Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase NA 2Phase 3 1

Status

Unknown 5Recruiting 5Terminated 3

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 3Head & Neck 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Lymphoma, Mantle-Cell 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell 1Locally Advanced Breast Cancer 1

Interventions

Cisplatin 267Oxaliplatin 194Carboplatin 189Capecitabine 183Docetaxel 176apatinib 164Paclitaxel 158Bevacizumab 155Gemcitabine 154Radiotherapy 146camrelizumab 145Fluorouracil 144Cyclophosphamide 123Irinotecan 119Drug Therapy 118sintilimab 107Etoposide 99anlotinib 90S 1 (combination) 88Leucovorin 85pembrolizumab 82Pemetrexed 78Doxorubicin 77toripalimab 76tislelizumab 75Dexamethasone 70Trastuzumab 65Neoadjuvant Therapy 64Rituximab 62Cetuximab 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Unknown × Clinical Protocols × Clear all
NCT06130007 2023-11-13

B2023-153

Sun Yat-sen University

Phase 2 Unknown
48 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05774028 2023-03-17

Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) in the Treatment of Untreated Early Non-upper Respiratory Tract or Advanced Extranodal NK/T-cell Lymphoma

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Unknown
50 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT05749016 2023-03-01

Neoadjuvant Inetetamab Combined With Pertuzumab and Paclitaxel/Carboplatin for Breast Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Unknown
30 enrolled
Breast

Locally Advanced Breast Cancer

NCT05744037 2023-02-24

Clinical Study of the Safety and Efficacy of the R/R B-NHL Regimen With BTK Inhibitor+Anti-CD19 CAR-T Cells

The Affiliated Hospital of Xuzhou Medical University

Phase 2 Unknown
30 enrolled
Lymphoid

Lymphoma, B-Cell

NCT00261612 2006-10-18

Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma

Medical University of Vienna

Phase 2 Unknown
16 enrolled
Lymphoid

Recurrence, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡